Options Trading News

May 1, 2013  Wed 9:46 AM CT

Allergan is down today, and the bears are piling in.

optionMONSTER's Depth Charge monitoring program detected the purchase of almost 5,000 May 110 puts, most of which priced for $2.40, against open interest of 1,545 contracts. They also snapped up more than 2,600 May 110s for $0.55 to $0.80.

Puts lock in the price where investors can sell shares in the Botox maker, no matter how low they go. That gives them a strong inverse correlation to the stock price, so they make money to the downside. (See our Education section)

AGN is down 7.22 percent to $105.35 this morning but is up 18 percent so far this year. The drug maker broke out to new all-time highs in January and kept climbing through early last month, when it started drifting lower.

Today's drop comes after the company forecast second-quarter earnings of no more than $1.20 a share, below the $1.22 expected by analysts. Sales were forecast at $1.50 billion to $1.575 billion, which suggests that it will also miss the $1.57 billion estimate.

Total option volume is 28 times greater than average in AGN so far today, with puts accounting for more than two-thirds of the total.

Disclosure: I own AGN shares.
Share this article with your friends

Invest Like a Monster - San Antonio: October 9-10


The fastest money in the market
View full report »

Premium Services

Archived Webinar

Education & Strategy

Options Academy: More on the Covered Call Strategy

Last week, we talked about the Covered Call and the misconceptions that surround it. We spoke about how an investor must realize that the Covered Call is actually a premium collection strategy and not so much a directional one. If an investor can grasp this idea, the investor stands to do a heck of a lot better in the strategy than they currently do.

View more education articles »